Phreesia (NYSE:PHR) Earns Buy Rating from Analysts at DA Davidson

Key Points

• DA Davidson has reaffirmed a buy rating for Phreesia (NYSE:PHR) with a price target of $33.00, indicating a potential upside of 5.41% from its previous close.
• The stock shows a consensus rating of buy from thirteen analysts, with recent price targets ranging from $32.00 to $35.00.
• Phreesia reported quarterly earnings surpassing estimates, with revenue of $117.26 million and a year-over-year increase of 14.9%.

DA Davidson started coverage on shares of Phreesia (NYSE:PHR - Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat.com reports. The firm set a "buy" rating and a $33.00 price target on the stock. DA Davidson's target price points to a potential upside of 24.48% from the company's current price.

Several other research analysts have also commented on PHR. Mizuho assumed coverage on shares of Phreesia in a report on Wednesday, August 27th. They issued an "outperform" rating and a $36.00 price target for the company. Citigroup restated a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Canaccord Genuity Group dropped their price target on Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research report on Thursday, May 29th. Truist Financial upped their price objective on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Finally, Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. One research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company. According to MarketBeat, Phreesia presently has an average rating of "Buy" and a consensus price target of $34.08.

Phreesia Stock Performance

Shares of NYSE PHR traded down $0.27 during trading on Friday, reaching $26.51. The stock had a trading volume of 1,156,052 shares, compared to its average volume of 571,548. Phreesia has a one year low of $17.07 and a one year high of $32.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a market cap of $1.58 billion, a PE ratio of -63.12 and a beta of 0.72. The firm's 50 day moving average price is $28.31 and its two-hundred day moving average price is $26.50.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.08. The firm had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative return on equity of 9.00% and a negative net margin of 5.35%.The firm's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the business posted ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. On average, research analysts forecast that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Allison C. Hoffman sold 1,245 shares of the stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $26.89, for a total value of $33,478.05. Following the completion of the transaction, the general counsel owned 136,978 shares in the company, valued at $3,683,338.42. This represents a 0.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm's stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $27.67, for a total transaction of $77,531.34. Following the transaction, the director directly owned 22,037 shares in the company, valued at approximately $609,763.79. The trade was a 11.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,292 shares of company stock valued at $3,295,323. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Phreesia by 2.4% during the first quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock worth $126,177,000 after purchasing an additional 113,405 shares in the last quarter. Greenhouse Funds LLLP increased its position in shares of Phreesia by 12.5% during the 2nd quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company's stock valued at $94,637,000 after purchasing an additional 368,352 shares during the period. Champlain Investment Partners LLC raised its stake in shares of Phreesia by 20.0% in the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after buying an additional 490,340 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Phreesia by 108.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after buying an additional 1,377,904 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Phreesia by 0.6% during the second quarter. Franklin Resources Inc. now owns 1,524,251 shares of the company's stock valued at $43,380,000 after buying an additional 9,057 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.